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Tetrathiomolybdate
First synthesis: J. J. Berzelius (1826) 
Identified as a copper-binding agent following observations 
of depletion of copper levels in ruminants caused by dietary 
molybdenum (1943-1975)
1785: First description of copper intoxication
(Thomas Percival, MD, FRS).
1912: ‘Progressive lenticular degeneration: a familial 
nervous disease associated with cirrhosis of the liver’. 
Wilson SAK, Brain, 1912, 34, 295.
1985
Preliminary report of the use of ammonium 
tetrathiomolybdate for treating Wilson’s disease. Walshe JM, 
Orphan Diseases and Orphan Drugs, eds. Scheinberg IH, 
Walshe JM., Manchester University  Press, 1986, pp 76-85.
1982
1975-1985
1975
1972
1969
1968
1956-1970s
Summarises use of trientine for treating Wilson’s 
disease. Walshe JM, Lancet, 1982, i, 643-647.
Problems concerning the analysis, supply, 
and Product Licence for trientine resolved. 
Expresses concerns about the supply of trientine. 
Walshe JM., Br. Med. J. (1975); 
New Scientist (1975).
Details for the preparation of trientine dihydrochloride
from technical grade triethylenetetramine published.
(Hitherto only the tetrahydrochloride had been reported).
Dixon HBF, Gibbs K, Walshe JM, Lancet, 1972, i,853.
First report of use of trientine dihydrochloride for 
treating Wilson’s disease. Walshe JM., Lancet, 1969, ii, 
1401-1402. Used initially for patients intolerant of D-
penicillamine.
With Dr H. B. F. (Hal) Dixon, links known copper 
chelating properties of trientine and resemblance 
to endogenous polyamines; they suggest trientine
could be used to treat Wilson’s disease. 
Difficulties with the supply of D-penicillamine 
overcome; manufacturing routes developed. 
Reviewed in Angew. Chem., Int. Ed. Engl. (1975).
1956
First report of D-penicillamine as oral therapy 
for Wilson’s disease. Walshe JM., Am. J. Med., 
1956, 21, 487-495; Lancet, 1956, 270, 25-26.
1955
Suggests D-penicillamine (for the first time) as a 
potential metal chelating agent. In particular, for 
removing copper in a patient with Wilson’s 
disease.
1951 - 1954
Identifies penicillamine in urine of patients with 
liver injury receiving penicillin. (Walshe JM, 
Q. J. Med., 1953, 22, 483).
1948: Elevated copper (and iron) levels found in brain and liver 
samples from Wilson’s disease patients.
Significance of reducing copper levels in Wilson’s disease 
patients realised.  
1951: BAL (British Anti-Lewisite) suggested as a rational 
(chelation) therapy. Treatment of Wilson’s disease with BAL
reported by various investigators. (See John N. Cumings,
Heavy Metals and the Brain, Blackwell, Oxford, 1959).
Penicillamine
Found to be a chemical degradation product of penicillins 
(1943)
Structure deduced by John Cornforth
Identified as the D-[or (S)-] isomer by Dorothy Crowfoot et al. 
Triethylenetetramine (trientine)
First synthesis: A. W. Hofmann (1860)
Complex with cupric sulfate studied (1936)
Stability complex with Cu(II) measured (1950)
Chelate effect defined (1952)
Treatment of Wilson’s disease was transformed in the 20th century by the introduction of four drugs, which could be administered orally: 
D-penicillamine, triethylenetetramine (trientine) dihydrochloride, zinc acetate and ammonium tetrathiomolybdate. 
Three of these four oral treatments – D-penicillamine, trientine and tetrathiomolybdate – owe their provenance to the diligence, 
perspicacity and intuition of the English physician, Dr John Walshe. 
Dr John Walshe
Background: Copper and Wilson’s disease
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